Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
About Index
Index
By TNW
Log in
Register
Novo Nordisk
178
Novo Nordisk
Technology
Biotechnology
Health Care
Medical
Pharmaceuticals
We are committed to #changingdiabetes & possibilities in #haemophilia. Sharing stories & updates from around the world. Disclaimer on our site
Suggest edits
Founded
1923
Follow us
Companies in the same industry
XtalPi
CGeneTech
ANTABIO
TOT BIOPHARM
PhagoMed Biopharma
Pharmaron Beijing Co.
ROME Therapeutics
Syracuse Biopharma
Clinevo Technologies
Roche
Alexa global traffic share
Twitter followers
Overview
Investments
1
Apps
1
Add info
Team Size
10000+
Employees
I work here
Location
Denmark
Headquarters
Explore Denmark
Pulse 2.0
Novo Nordisk (NVO) Stock: $130 Price Target And Outperform Rating
Pulse 2.0
,
MedCity News
Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion
FinSMEs
Novo Nordisk to Buy Corvidia Therapeutics, for Up To $2.1 Billion
Crunchbase News
Novo Nordisk To Buy Corvidia Therapeutics For Up To $2.1B
Xconomy
Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia
Bloomberg Technology
Novo Nordisk Joins Other Drugmakers With Gains on Virus Stockpiling
Xconomy
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Xconomy
Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate
Reuters Top News
Novo Nordisk targets bigger slice of diabetes market with new tablet
Reuters Top News
Novo Nordisk to cut insulin prices in the U.S.
Reuters Top News
Denmark's Novo Nordisk files lawsuit against Mylan over patent
Reuters Top News
Novo Nordisk profit tops forecast as new diabetes drug shines
MedCity News
Taiwanese startup Health2Sync inks Novo Nordisk deal to drive growth in Japan
GeekWire
Novo Nordisk teaming up with startups for diabetes challenge, aiming to create new digital health tools
Xconomy
Eli Lilly Strikes Deal for Diabetes Pill to Gain on Novo Nordisk
Bloomberg
Novo Nordisk Is on High But Shaky Ground
Health
Earnings
Bloomberg
Novo Nordisk's Deal Discipline Is Behind the Times
Health
Stock markets
Bloomberg
Novo Goes Public With $3.1 Billion Bid to Pressure Ablynx
Health
Strategy
Xconomy
Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test
Health
Earnings
The Motley Fool
What Is It About Novo Nordisk's Diabetes Drug That Makes It a Top Seller?
Health